Logo
x

Search

Subscribe Now

Adalimumab

Insights+ Key Biosimilars Events of October 2023

Insights+ Key Biosimilars Events of October 2023

  • November 1, 2023
Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

  • November 8, 2021
Pfizer Seeks to Obtain Interchangeable Status for Abrilada (biosimilar, adalimumab)

Pfizer Seeks to Obtain Interchangeable Status for Abrilada (biosimilar, adalimumab)

  • November 4, 2021
Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

  • May 5, 2021
Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada

Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada

  • March 30, 2021
Innovent's Sulinno (biosimilar- adalimumab) Receives NMPA's Approval for Autoimmune Diseases

Innovent's Sulinno (biosimilar- adalimumab) Receives NMPA's Approval for Autoimmune Diseases

  • September 4, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.